Spruce Biosciences, Inc. (NASDAQ:SPRB) Stock Has Average Target Price of $158.33

Posted by Brenda Bartman on Oct 20th, 2026

Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $158.33.

Several research analysts have recently issued reports on the company. The Goldman Sachs Group raised Spruce Biosciences to an “overweight” rating in a research note on Thursday, August 13th. B. Riley Financial started coverage on shares of Spruce Biosciences in a report on Monday, July 13th. They issued a “buy” rating and a $160.00 price target on the stock. Citigroup reaffirmed a “market outperform” rating on shares of Spruce Biosciences in a report on Friday, September 18th. HC Wainwright reiterated a “buy” rating on shares of Spruce Biosciences in a research report on Wednesday, August 26th. Finally, Wall Street Zen cut Spruce Biosciences from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th.

Check Out Our Latest Stock Report on SPRB

Spruce Biosciences Stock Performance

NASDAQ SPRB opened at $40.40 on Tuesday. The business has a 50 day moving average price of $51.20 and a 200 day moving average price of $52.35. The company has a market capitalization of $115.95 million, a P/E ratio of -1.02 and a beta of 3.25. Spruce Biosciences has a 1-year low of $38.06 and a 1-year high of $154.95. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.23 and a quick ratio of 9.23.

Spruce Biosciences (NASDAQ:SPRB – Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($6.68) EPS for the quarter, missing analysts’ consensus estimates of ($5.79) by ($0.89). Sell-side analysts expect that Spruce Biosciences will post -25.53 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SPRB. AWM Investment Company Inc. acquired a new stake in shares of Spruce Biosciences during the 2nd quarter worth about $7,937,000. Bank of New York Mellon Corp purchased a new stake in Spruce Biosciences in the 2nd quarter worth approximately $366,000. Stempoint Capital LP purchased a new stake in Spruce Biosciences in the 1st quarter worth approximately $416,000. Pale Fire Capital SE purchased a new stake in Spruce Biosciences in the 2nd quarter worth approximately $206,000. Finally, SkyView Investment Advisors LLC purchased a new stake in Spruce Biosciences in the 2nd quarter worth approximately $162,000. 91.71% of the stock is currently owned by hedge funds and other institutional investors.

About Spruce Biosciences

(Get Free Report)

Spruce Biosciences, Inc is a biotechnology company focused on developing medicines for rare endocrine disorders. The company’s research centers on conditions in which abnormal hormone production creates significant health complications and limited treatment options.

Spruce’s lead product candidate is tildacerfont, an investigational, orally administered selective corticotropin-releasing factor type 1 receptor antagonist. The therapy is designed to regulate the hypothalamic-pituitary-adrenal axis and reduce excessive adrenocorticotropic hormone and adrenal androgen production.